Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Bristol-Myers Squibb's decision not to seek accelerated FDA approval for its Opdivo/Yervoy combo in early lung cancer shocked investors - but analysts still expect a filing to come, albeit later than first thought.

Plan B

Merck & Co. Inc. received some unexpected good news late Jan. 19 when rival Bristol-Myers Squibb Co. said it wouldn't apply for accelerated US approval for its combination of Opdivo (anti-PD-1) plus Yervoy (ipilimumab; anti-CTLA-4) as a first-line treatment for non-small cell lung cancer (NSCLC). The move puts Bristol's IO combo's prospects even further behind Merck's Keytruda (pembrolizumab), which last week was accepted for accelerated review in that indication by the FDA in combination with chemotherapy.

Bristol, in a terse announcement, said it made the decision to hold early fire based on "a review of data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.